StockData
LifeMD, Inc. logo

LifeMD, Inc. (LFMDP) stock

LFMDPNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as LFMD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 10/3099% above fair value
$21.65+0.13 (+0.60%)

Close on Oct 30, 2026Market cap $110.38MP/E –Yield –

Earnings

LifeMD's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 16, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$47.30M
-24.0% on a year earlier
Adjusted EPS, Q2 FY2026
-$0.16
-$0.06 a year earlier
Latest guidance
Lowered
Aug 5, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of LifeMD's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 16, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$47.30M-24.0%-$0.16–Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$50.20M-23.6%-$0.20–Release
Q4 FY2025ended Dec 31, 2025Mar 9, 2026after the close$46.90M-27.0%-$0.04–Release
Q3 FY2025ended Sep 30, 2025Nov 17, 2025after the close$60.20M–-$0.10–Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$62.20M–-$0.06–Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$65.70M–$0.01–Release
Q4 FY2024ended Dec 31, 2024Mar 10, 2025after the close$64.25M–-$0.02$0.21Release
Q4 FY2021ended Dec 31, 2021Jan 19, 2022during market hours$27.40M–––Release
Q1 FY2021ended Mar 31, 2021Apr 19, 2021after the close––––Filing
Q4 FY2020ended Dec 31, 2020Jan 19, 2021after the close––––Filing
Q3 FY2016ended Sep 30, 2016Oct 12, 2016during market hours––––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

LifeMD's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueQ3 FY2026$48.00M – $51.00M–NewAug 5, 2026
Adjusted EBITDAnon-GAAPQ3 FY2026-$1.00M – $2.00M–NewAug 5, 2026
revenueQ4 FY2026$60.00M – $64.00M–NewAug 5, 2026
adjusted EBITDAnon-GAAPQ4 FY2026$3.00M – $6.00M–NewAug 5, 2026
RevenueFY2026$205.50M – $212.50M$220.00M – $230.00MLoweredAug 5, 2026
year-over-year growthFY2026+13% – +19%+13% – +19%ReaffirmedMay 6, 2026
Adjusted EBITDAnon-GAAPFY2026$12.00M – $17.00M$12.00M – $17.00MReaffirmedMay 6, 2026

Guidance vs results

The last range LifeMD gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q2 FY2026Revenue$47.00M – $50.00M$47.30MWithin range
Q1 FY2026Revenue$48.00M – $49.00M$50.20MAbove range
FY2025Revenue$192.00M – $193.00M$235.00MΣ4QAbove range
Q4 FY2025Revenue$45.00M – $46.00M$46.90MAbove range
Q3 FY2025Revenue$48.00M – $50.00M$60.20MAbove range
Q2 FY2025Revenue$52.00M – $53.00M$62.20MAbove range
Q1 FY2025Revenue$48.00M – $49.00M$65.70MAbove range

Guidance history

Every forecast LifeMD put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026adjusted EBITDAQ4 FY2026$3.00M – $6.00MNew
Aug 5, 2026Adjusted EBITDAQ3 FY2026-$1.00M – $2.00MNew
Aug 5, 2026revenueQ4 FY2026$60.00M – $64.00MNew
Aug 5, 2026RevenueFY2026$205.50M – $212.50MLowered
Aug 5, 2026RevenueQ3 FY2026$48.00M – $51.00MNew
May 6, 2026Adjusted EBITDAFY2026$12.00M – $17.00MReaffirmed
May 6, 2026Adjusted EBITDAQ2 FY2026-$2.00M – $1.00MNew
May 6, 2026year-over-year growthFY2026+13% – +19%Reaffirmed
May 6, 2026RevenueQ2 FY2026$47.00M – $50.00MNew
May 6, 2026RevenueFY2026$220.00M – $230.00MReaffirmed
Mar 9, 2026Adjusted EBITDA lossQ1 FY2026-$5.00M – -$4.00MNew
Mar 9, 2026Adjusted EBITDAFY2026$12.00M – $17.00MNew
Mar 9, 2026RevenueQ1 FY2026$48.00M – $49.00MNew
Mar 9, 2026RevenueFY2026$220.00M – $230.00MNew
Mar 9, 2026year-over-year growthFY2026+13% – +19%New
Nov 17, 2025Adjusted EBITDAQ4 FY2025$3.00M – $4.00MNew
Nov 17, 2025Adjusted EBITDAFY2025$13.50M – $14.50MNew
Nov 17, 2025RevenueQ4 FY2025$45.00M – $46.00MNew
Nov 17, 2025RevenueFY2025$192.00M – $193.00MNew
Aug 5, 2025Adjusted EBITDAQ3 FY2025$6.00M – $7.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases LifeMD filed with the SEC as exhibits to Form 8-K or 6-K

  1. Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD
    Update
  2. Reports Second Quarter 2026 Results
    Results
  3. Quarterly results release
    Results
  4. Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
    Update
  5. Reports First Quarter 2026 Results
    Results
  6. Quarterly results release
    Results
  7. Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
    News
  8. Reports Fourth Quarter and Full Year 2025 Results
    Results
  9. Quarterly results release
    Results
  10. Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
    Update
  11. Reports Third Quarter 2025 Results
    Results
  12. Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
    Update
  13. Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
    Update
  14. LifeMD Reports Second Quarter 2025 Results
    Results
  15. Names COO and Promotes Two Executives
    News